Science & technology | Treating dementia
A drug for Alzheimer’s disease that seems to work
It is not perfect. And it has side-effects. But it may be the real deal
Editor’s note: On January 6th America’s Food and Drug Administration approved lecanemab, to be marketed as Leqembi.
This article appeared in the Science & technology section of the print edition under the headline “Enter lecanemab”
From the December 3rd 2022 edition
Discover stories from this section and more in the list of contents
Explore the editionMore from Science & technology
Should you worry about microplastics?
Little is known about the effects on humans—but limiting exposure to them seems prudent
Wasps stole genes from viruses
That probably assisted their evolutionary diversification
America’s departure from the WHO would harm everyone
Whether it is a negotiating ploy remains to be seen
Genetic engineering could help rid Australia of toxic cane toads
It is better than freezing them to death
High-tech antidotes for snake bites
Genetic engineering and AI are powering the search for antivenins
Can you breathe stress away?
It won’t hurt to try. But scientists are only beginning to understand the links between the breath and the mind